Search clinical trials for: inadequate response

Total 13530 results

AbbVie

Recruiting

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up)

Atopic Dermatitis

United States
Ipsen

Not yet recruiting

A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE)

Primary Biliary Cholangitis
Clexio Biosciences Ltd.

Recruiting

A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder (SOLEO)

Adjunctive Treatment of Major Depressive Disorder (MDD)

United States
Kowa Research Institute, Inc.

Recruiting

Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.

Primary Biliary Cholangitis

United States, Japan
Sanofi

Recruiting

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor (AQUA)

Dermatitis Atopic

Chile, United Kingdom, United States, Canada, Turkey, Israel, Korea, Republic of
Merck Sharp & Dohme LLC

Recruiting

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

Essential Thrombocythemia

Israel, Australia, Hong Kong, Japan, New Zealand, Taiwan, Korea, Republic of, United States, Spain, Italy
Hangzhou Highlightll Pharmaceutical Co., Ltd

Recruiting

A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs (TARA)

Rheumatoid Arthritis

China
Aqtual, Inc.

Recruiting

Prospective, Multi-Center, Observational, Whole Blood Specimen Collection Study in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to a DMARD Starting a New bDMARD or tsDMARD Treatment +/- csDMARD (PRIMA-102)

Rheumatoid Arthritis

United States
Janssen Research & Development, LLC

Recruiting

A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI) (VENTURA-RWE)

Depressive Disorder, Major

United States, Korea, Republic of, Spain, Argentina, United Kingdom, Sweden, Italy, Germany, France, Canada, Brazil
Novartis Pharmaceuticals

Recruiting

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

Chronic Spontaneous Urticaria

United States, Singapore, Spain, Germany, Turkey, Italy, Hong Kong, China, Argentina, Malaysia, Thailand, Poland, Japan, Netherlands, Chile, Canada
NovelMed Therapeutics

Not yet recruiting

Study of NM8074 in Adult PNH Patients With Inadequate Response to Soliris

Paroxysmal Nocturnal Hemoglobinuria
SynAct Pharma Aps
NBCD A/S

Recruiting

A Dose-range Study of the Safety and Efficacy of Treatment in Adult Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate (RESOLVE)

Rheumatoid Arthritis

Moldova, Republic of
Janssen Research & Development, LLC

Recruiting

A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy (VENTURA-2)

Anhedonia | Depressive Disorder, Major

Korea, Republic of, United States, China, Taiwan, Slovakia, Brazil, Poland, Argentina, Bulgaria, Czechia, South Africa, Canada, United Kingdom, France
Axsome Therapeutics, Inc.

Recruiting

Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE)

Migraine

United States
Pfizer

Recruiting

Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications

Migraine

Spain, Canada, United States, Poland, Belgium, Finland, Denmark, Austria, Italy, Sweden, Germany, Australia, United Kingdom, Mexico
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy

Crohn Disease

United States, Belgium, Hungary, France, Canada, Spain, Australia, Germany, Poland, United Kingdom
Janssen Research & Development, LLC

Recruiting

A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy (VENTURA-1)

Anhedonia | Depressive Disorder, Major

United States, Spain, Bulgaria, Italy, Poland, Belgium, Argentina, Czechia, Hungary, Sweden, Brazil, Australia, Portugal
Atsushi Kawakami
Gilead Sciences

Recruiting

Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate (TRANSFORM)

Rheumatoid Arthritis | Biomarker | JAK Inhibitor | Musculoskeletal Ultrasound | IL-6 Inhibitor

Japan
Janssen Research & Development, LLC

Recruiting

Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent (SOLSTICE)

Arthritis, Psoriatic

Israel, Turkey, United States, Hungary, Spain, Australia, Bulgaria, Czechia, Malaysia, Poland, Puerto Rico, Russian Federation, Ukraine, Argentina
Assistance Publique - Hôpitaux de Paris
URC-CIC Paris Descartes Necker Cochin

Not yet recruiting

Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis (SATELITE)

Granulomatosis With Polyangiitis | Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis

France
Xijing Hospital of Digestive Diseases

Recruiting

Fenofibrate for Patients With Primary Biliary Cirrhosis Who Had An Inadequate Response to Ursodeoxycholic Acid

Primary Biliary Cirrhosis

China
AstraZeneca

Completed

Study Will Assess the Safety, Neutralizing Activity and Efficacy of AZD3152 in Adults With Conditions Increasing Risk of Inadequate Protective Immune Response After Vaccination and Thus Are at High Risk of Developing Severe COVID-19 (NOVELLA)

COVID-19, SARS-CoV-2

Russian Federation
Janssen Research & Development, LLC

Active, not recruiting

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents With Major Depressive Disorder Who Have an Inadequate Response to Selective Serotonin Reuptake Inhibitor (SSRI) and Psychotherapy

Depressive Disorder, Major

United States, Spain, Italy, United Kingdom
Astellas Pharma China, Inc.

Completed

A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)

Rheumatoid Arthritis (RA)

China, Korea, Republic of, Taiwan
GlaxoSmithKline
Iqvia Pty Ltd

Completed

Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate (contRAst 1)

Arthritis, Rheumatoid

Hungary, Poland, Malaysia, Spain, China, Russian Federation, India, United Kingdom, Italy, Serbia
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effects of Multiple Rising Subcutaneous Doses of BI 655064 in Healthy Volunteers and in Rheumatoid Arthritis Patients With Prior Inadequate Response to Methotrexate Therapy

Healthy | Arthritis, Rheumatoid

Germany, Netherlands, New Zealand, Poland, Spain, Czechia
Kiniksa Pharmaceuticals, Ltd.

Active, not recruiting

Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor

Arthritis, Rheumatoid

United States, Poland, Hungary, Georgia, Czechia, South Africa, Bulgaria
BioCryst Pharmaceuticals

Terminated

BCX9930 for Treatment of PNH in Subjects With Inadequate Response to C5 Inhibitor Therapy (REDEEM-1)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United Kingdom, Hungary, France, Italy, Spain
LEO Pharma

Terminated

Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab (COBRA)

Psoriasis | Plaque Psoriasis | Psoriasis Vulgaris

Belgium, Germany, Italy, Spain, Denmark, Austria, France, Greece, Switzerland, United Kingdom, Netherlands, Sweden
AbbVie

Completed

A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)

Rheumatoid Arthritis

United States, Argentina, Australia, Austria, Belgium, Bulgaria, Chile, Czechia, Estonia, Greece, Hungary, Israel, Italy, Japan, Mexico, Poland, Portugal, Puerto Rico, Romania, Russian Federation, Serbia, South Africa, Spain, Turkey, Uk...
Alexion Pharmaceuticals, Inc.
Achillion, a wholly owned subsidiary of Alexion

Completed

Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab (PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United Kingdom, United States, Italy
GlaxoSmithKline
Iqvia Pty Ltd

Terminated

Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs) (contRAst 2)

Arthritis, Rheumatoid

United States, Australia, Germany, Japan, Korea, Republic of, Poland, Bulgaria, Estonia, Hungary, Mexico, Russian Federation, Spain, Thailand, Colombia, China, Argentina, United Kingdom, France
Hoffmann-La Roche

Completed

An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) Therapy

Rheumatoid Arthritis

China
AbbVie

Active, not recruiting

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) (SELECT - PsA 1)

Psoriatic Arthritis

United States, Argentina, Australia, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic... and more
AbbVie

Active, not recruiting

A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) (SELECT - PsA 2)

Psoriatic Arthritis

United States, Belgium, Brazil, Canada, Chile, Czechia, France, Greece, Hungary, Italy, Japan, Netherlands, New Zealand, Portugal, Puerto Rico, Spain, United Kingdom
Janssen Research & Development, LLC

Terminated

A Standard of Care Study of Patients With Major Depressive Disorder Who Have Had an Inadequate Response to a Selective Serotonin Reuptake/Serotonin-Norepinephrine Reuptake Inhibitor Antidepressant

Depressive Disorder, Major

United States, United Kingdom
Bristol-Myers Squibb

Active, not recruiting

A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Rheumatoid Arthritis

Italy, United States, Germany, Argentina, Australia, Czechia, France, Japan, Mexico, Poland, Spain, Switzerland, Taiwan, United Kingdom
CymaBay Therapeutics, Inc.

Completed

RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)

Primary Biliary Cholangitis

United States, Spain, France, Korea, Republic of, Denmark, Australia, Italy, United Kingdom, Belgium, Canada, Russian Federation, Romania, Germany, Hungary, Mexico, Turkey, Argentina, Austria, Chile, Czechia, Greece, Israel, New Zealand and more
Galderma R&D

Withdrawn

Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to or for Whom Cyclosporine A is Not Medically Advisable

Moderate-to-severe Atopic Dermatitis
RemeGen Co., Ltd.

Completed

A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.

Moderate and Severe RheumatoId Arthritis

China
GlaxoSmithKline
Iqvia Pty Ltd

Completed

Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors (contRAst 3)

Arthritis, Rheumatoid

United States, Germany, Canada, Czechia, Poland, South Africa, Korea, Republic of, Spain, Japan, Argentina, Belgium, Hungary, United Kingdom, Italy, Lithuania
Bristol-Myers Squibb

Completed

Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)

Active Polyarticular Juvenile Idiopathic Arthritis

United States, Spain, Belgium, Italy, Argentina, Brazil, France, Germany, Mexico, Peru, Russian Federation, South Africa
AbbVie

Completed

A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs

Rheumatoid Arthritis (RA)

United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Czechia, Germany, Greece, Hungary, Ireland, Israel, Italy, Korea, Republic of, Latvia, Mexico, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Romania, Russian... and more
Jazz Pharmaceuticals

Terminated

Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment

Schizophrenia

United States, Spain, Poland, Serbia
AbbVie

Completed

A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs (SELECTSUNRISE)

Rheumatoid Arthritis

Japan
AbbVie

Active, not recruiting

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) (KEEPsAKE2)

Psoriatic Arthritis (PsA)

United States, Argentina, Australia, Belgium, Brazil, Canada, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Singapore, South Africa, Spain, Sweden, United...
AbbVie

Active, not recruiting

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (KEEPsAKE 1)

Psoriatic Arthritis

United States, Argentina, Australia, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, Croatia, Czechia, Denmark, Estonia, Finland, Germany, Greece, Israel, Italy, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico and more
AbbVie

Active, not recruiting

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate (SELECT-COMPARE)

Rheumatoid Arthritis

United States, Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, Colombia, Croatia, Czechia, Denmark, Estonia, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, ... and more
AbbVie

Completed

A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone (SELECT-NEXT)

Rheumatoid Arthritis

United States, Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Czechia, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, Ireland, Italy, Kazakhstan, Korea, Republic of, Latvia, Lithuan... and more
Pfizer

Completed

TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE

Rheumatoid Arthritis

Czechia, Hungary, Spain, Poland, Canada, Bulgaria, Chile, Georgia, Slovakia, Ukraine

3

Subscribe